Next Generation Cancer Diagnostics Market Size & Forecast By Technology, By Function, By Cancer Type, By Application And Trend Analysis From 2015 To 2022

Description:

Global next generation cancer diagnostics market is anticipated to reach USD 20.25 billion by 2022 growing at an estimated CAGR of 32.0% from 2015 to 2022. Rising incidence of oncology diseases is anticipated to drive the demand for next generation cancer diagnostic tests that are expected to enhance early diagnosis and efficient prognosis of various forms of cancers is a factor expected to positively influence sector growth over the forecast period.

Cancer diagnostics industry is estimated to witness lucrative growth over the forecast period majorly due to rising number of technologically advanced products in the field of companion diagnostics, providing more precise testing results combined with therapeutic monitoring early diagnosis of cancer. Moreover, there is a significant shift observed from traditional laboratory testing to rapid point of care testing, which fuels growth in the market owing to expected commercialization of technologically advanced range of products including diagnostic kits, instruments, and reagents.

Furthermore, supportive government initiatives in order to increase the number of research projects with respect to oncology and preventative diagnosis is expected to be attributive for growth in this sector over the coming years. Additionally, application of tumor diagnostics in epigenetic analysis and CTC enumeration for monitoring tumorigenesis is expected to support projected growth over the forecast period.

Further key findings from the report suggest:

RT-PCR & multiplexing accounted for the largest share of the market in 2014 with respect to technologies because of the presence of a wide product portfolio that caters to a number of applications in oncology R&D.

Next generation sequencing solutions for use in cancer diagnostics are expected to witness lucrative growth in revenue over the forecast period owing to the considerable number of advantages the technology offers over its counterpart segment i.e. microarrays. Introduction of novel sequencing platforms and growth oriented initiatives taken by major market participants are other key factors expected to fuel segment growth.

In January 2016, Illumina launched its MiniSeq system for the sequencing, which provides complete sequencing solution in order to obtain quicker results because of onboard data analysis for numerous assays and workflow with easy-to-use library-to-results. Such strategic initiatives taken by major market entities are also expected to drive this segment further over the forecast period.

Development and expected commercialization of a number of companion diagnostics is a key factor attributive of anticipated substantial growth in demand and progress of the segment over the next seven years owing to rising sector penetration in this segment for use with therapeutics and novel pharmaceuticals as adjunct in monitoring tumor eradication.

Dominant industry participants to produce non-small cell lung cancer diagnostic tests anticipate lung cancer to witness substantial growth in market demand because of product development operations carried out. Application of oncology diagnostics in biomarker discovery by transcription regulation is expected to drive industry with potential growth avenues as it subsequently proves helpful in drug designing and identification of novel targets for tumor eradication.

North America held the largest share with respect to revenue generation in 2014 due to simultaneous development of next generation sequencing, personalized medicine and companion diagnostics in the region. Furthermore, high R&D investment as well as availability of technologically advanced healthcare research framework, is expected to serve as a critical factor for the North American region to register considerable growth over the forecast period.

Presence of significant developments by China and Japan for technological integration, and the development of healthcare infrastructure have poised the Asia Pacific oncology diagnostics market to witness lucrative opportunities of growth throughout the forecast period. Moreover, enhancements of clinical development frameworks in these economies to enable clinical research outsourcing as an effect of the availability of target population is a growth rendering driver in this region.

Key players contributing significantly to the next generation cancer diagnostics market are Novartis AG,

These entities are involved in collaborations with oncology research organizations and clinical research institutes in order to gain access in the oligopolistic market.

Contents:
1. Methodology and Scope
   1.1. Research Methodology
   1.2. Research Scope & Assumptions
   1.3. List of Data Sources

2. Executive Summary

3. Next Generation Cancer Diagnostics Industry Outlook
   3.1. Market Segmentation
   3.2. Market Size and Growth Prospects
   3.2.1. Market Driver Analysis
   3.2.2. Market Restraint Analysis
   3.3. Next Generation Cancer Diagnostics Market Dynamics
   3.4. Key Opportunities Prioritized, 2014
   3.5. Industry Analysis - Porter’s
   3.6. Next Generation Cancer Diagnostics Market PESTEL Analysis

4. Next Generation Cancer Diagnostics Technology Outlook
   4.1. DNA Microarrays
   4.1.1. DNA Microarrays Market Estimates and Forecasts, 2015 - 2022 (USD Million)
   4.2. Protein Microarrays
   4.2.1. Protein Microarrays Market Estimates and Forecasts, 2015 - 2022 (USD Million)
   4.3. Lab-on-a-chip
   4.3.1. Lab-on-a-chip Market Estimates and Forecasts, 2015 - 2022 (USD Million)
   4.4. RT-PCR & Multiplexing
   4.4.1. RT-PCR & Multiplexing Market Estimates and Forecasts, 2015 - 2022 (USD Million)
   4.5. NGS Sequencing
   4.5.1. NGS Sequencing Market Estimates and Forecasts, 2015 - 2022 (USD Million)

5. Next Generation Cancer Diagnostics Outlook, By Function
   5.1. Risk Analysis
   5.1.1. Risk Analysis Market Estimates and Forecasts, 2015 - 2022 (USD Million)
   5.2. Cancer Screening
   5.3. Prognosis Diagnostics
   5.3.1. Prognosis Diagnostics Market Estimates and Forecasts, 2015 - 2022 (USD Million)
   5.4. Therapeutic Monitoring
   5.4.1. Therapeutic Monitoring Market Estimates and Forecasts, 2015 - 2022 (USD Million)
   5.5. Companion Diagnostics
   5.5.1. Companion Diagnostics Market Estimates and Forecasts, 2015 - 2022 (USD Million)

6. Next Generation Cancer Diagnostics Application Outlook
   6.1. Genetic Analysis
   6.2. Epigenetic Analysis
   6.3. CTC Analysis
   6.3.1. CTC Analysis Market Estimates and Forecasts, 2015 - 2022 (USD Million)
   6.4. Proteomic Analysis
   6.5. Biomarker Development

7. Next Generation Cancer Diagnostics Outlook, By Cancer Type
   7.1. Breast Cancer
7.2. Cervical Cancer
7.3. Colorectal Cancer
7.3.1. Colorectal Cancer Market Estimates and Forecasts, 2015 - 2022 (USD Million)
7.4. Lung Cancer
7.4.1. Lung Cancer Market Estimates and Forecasts, 2015 - 2022 (USD Million)
7.5. Others
7.5.1. Others Market Estimates and Forecasts, 2015 - 2022 (USD Million)

8. Next Generation Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2015 - 2022)
8.1. North America
8.1.1. U.S.
8.1.1.1. Market, by technology, 2015 - 2022 (USD Million)
8.1.1.2. Market, by function, 2015 - 2022 (USD Million)
8.1.1.3. Market, by cancer type, 2015 - 2022 (USD Million)
8.1.1.4. Market, by application, 2015 - 2022 (USD Million)
8.1.2. Canada
8.1.2.1. Market, by technology, 2015 - 2022 (USD Million)
8.1.2.2. Market, by function, 2015 - 2022 (USD Million)
8.1.2.3. Market, by cancer type, 2015 - 2022 (USD Million)
8.1.2.4. Market, by application, 2015 - 2022 (USD Million)
8.2. Europe
8.2.1. Germany
8.2.1.1. Market, by technology, 2015 - 2022 (USD Million)
8.2.1.2. Market, by function, 2015 - 2022 (USD Million)
8.2.1.3. Market, by cancer type, 2015 - 2022 (USD Million)
8.2.1.4. Market, by application, 2015 - 2022 (USD Million)
8.2.2. UK
8.2.2.1. Market, by technology, 2015 - 2022 (USD Million)
8.2.2.2. Market, by function, 2015 - 2022 (USD Million)
8.2.2.3. Market, by cancer type, 2015 - 2022 (USD Million)
8.2.2.4. Market, by application, 2015 - 2022 (USD Million)
8.2.3. France
8.2.3.1. Market, by technology, 2015 - 2022 (USD Million)
8.2.3.2. Market, by function, 2015 - 2022 (USD Million)
8.2.3.3. Market, by cancer type, 2015 - 2022 (USD Million)
8.2.3.4. Market, by application, 2015 - 2022 (USD Million)
8.3. Asia Pacific
8.3.1. China
8.3.1.1. Market, by technology, 2015 - 2022 (USD Million)
8.3.1.2. Market, by function, 2015 - 2022 (USD Million)
8.3.1.3. Market, by cancer type, 2015 - 2022 (USD Million)
8.3.1.4. Market, by application, 2015 - 2022 (USD Million)
8.3.2. Japan
8.3.2.1. Market, by technology, 2015 - 2022 (USD Million)
8.3.2.2. Market, by function, 2015 - 2022 (USD Million)
8.3.2.3. Market, by cancer type, 2015 - 2022 (USD Million)
8.3.2.4. Market, by application, 2015 - 2022 (USD Million)
8.4. Latin America
8.4.1. Brazil
8.4.1.1. Market, by technology, 2015 - 2022 (USD Million)
8.4.1.2. Market, by function, 2015 - 2022 (USD Million)
8.4.1.3. Market, by cancer type, 2015 - 2022 (USD Million)
8.4.1.4. Market, by application, 2015 - 2022 (USD Million)
8.5. MEA
8.5.1. South Africa
8.5.1.1. Market, by technology, 2015 - 2022 (USD Million)
8.5.1.2. Market, by function, 2015 - 2022 (USD Million)
8.5.1.3. Market, by cancer type, 2015 - 2022 (USD Million)
8.5.1.4. Market, by application, 2015 - 2022 (USD Million)

9. Competitive Landscape
9.1. Johnson & Johnson
9.1.1. Company Overview
9.1.2. Revenue Analysis
9.1.3. Product Benchmarking
9.1.4. Strategic Development
9.2. Novartis AG
9.2.1. Company Overview
9.2.2. Revenue Analysis
9.2.3. Product Benchmarking
9.2.4. Strategic Development
9.3. Roche Holding AG
9.3.1. Company Overview
9.3.2. Revenue Analysis
9.3.3. Product Benchmarking
9.3.4. Strategic Development
9.4. Philips Electronics NV
9.4.1. Company Overview
9.4.2. Revenue Analysis
9.4.3. Product Benchmarking
9.4.4. Strategic Development
9.5. Abbott Laboratories
9.5.1. Company Overview
9.5.2. Revenue Analysis
9.5.3. Product Benchmarking
9.5.4. Strategic Development
9.6. GE Healthcare
9.6.1. Company Overview
9.6.2. Revenue Analysis
9.6.3. Product Benchmarking
9.6.4. Strategic Development
9.7.1. Company Overview
9.7.2. Revenue Analysis
9.7.3. Product Benchmarking
9.7.4. Strategic Development
9.8. Agilent Technologies Inc
9.8.1. Company Overview
9.8.2. Revenue Analysis
9.8.3. Product Benchmarking
9.8.4. Strategic Development
9.9. Perkin Elmer Inc.
9.9.1. Company Overview
9.9.2. Revenue Analysis
9.9.3. Product Benchmarking
9.9.4. Strategic Development
9.10. Illumina Inc.
9.10.1. Company Overview
9.10.2. Revenue Analysis
9.10.3. Product Benchmarking
9.10.4. Strategic Development
9.11. Qiagen
9.11.1. Company Overview
9.11.2. Revenue Analysis
9.11.3. Product Benchmarking
9.11.4. Strategic Development
9.12.1. Company Overview
9.12.2. Revenue Analysis
9.12.3. Product Benchmarking
9.12.4. Strategic Development
9.13.1. Company Overview
9.13.2. Revenue Analysis
List of Tables

1. Next generation cancer diagnostics market - Industry Snapshot & Key Buying Criteria, 2015 - 2022
2. Global next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
5. Global next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
7. Next generation cancer diagnostics- Key market driver analysis
8. Next generation cancer diagnostics- Key market restraint analysis
17. Canada next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
18. Canada next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
20. Canada next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
21. Europe next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
22. Europe next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
23. Europe next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
24. Europe next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
25. Germany next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
26. Germany next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
27. Germany next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
28. Germany next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
List of Figures

1. Next generation cancer diagnostics market segmentation
2. Global next generation cancer diagnostics market, 2015 - 2022 (USD Million)
3. Next generation cancer diagnostics market dynamics
4. Key opportunities prioritized, 2014
5. Next generation cancer diagnostics market - Porter's Analysis
6. Next generation cancer diagnostics market - PESTEL analysis
7. Next generation cancer diagnostics revenue share, by technology, 2014 & 2022
8. DNA microarray market, 2015 - 2022 (USD Million)
9. Protein microarray market, 2015 - 2022 (USD Million)
10. Lab-on-a-chips market, 2015 - 2022 (USD Million)
11. RT-PCR & multiplexing market, 2015 - 2022 (USD Million)
12. NGS sequencing market, 2015 - 2022 (USD Million)
13. Next generation cancer diagnostics revenue share, by function, 2014 & 2022
15. Cancer screening market, 2015 - 2022 (USD Million)
16. Prognosis diagnostics market, 2015 - 2022 (USD Million)
17. Therapeutic monitoring market, 2015 - 2022 (USD Million)
18. Companion diagnostics market, 2015 - 2022 (USD Million)
20. Breast cancer market, 2015 - 2022 (USD Million)
22. Colorectal cancer market, 2015 - 2022 (USD Million)
23. Unknown primary cancer market, 2015 - 2022 (USD Million)
24. Leukemia market, 2015 - 2022 (USD Million)
25. Lung cancer market, 2015 - 2022 (USD Million)
26. Prostate cancer market, 2015 - 2022 (USD Million)
27. Other cancer market, 2015 - 2022 (USD Million)
29. Genetic analysis market, 2015 - 2022 (USD Million)
30. Epigenetic analysis market, 2015 - 2022 (USD Million)
31. CTC analysis market, 2015 - 2022 (USD Million)
32. Proteomic analysis market, 2015 - 2022 (USD Million)
33. Biomarker development market, 2015 - 2022 (USD Million)
34. Next generation cancer diagnostics revenue share, by region, 2014 & 2022
35. North America next generation cancer diagnostics market, 2015 - 2022 (USD Million)
37. Canada next generation cancer diagnostics market, 2015 - 2022 (USD Million)
38. Europe next generation cancer diagnostics market, 2015 - 2022 (USD Million)
39. Germany next generation cancer diagnostics market, 2015 - 2022 (USD Million)
40. UK next generation cancer diagnostics market, 2015 - 2022 (USD Million)
41. France next generation cancer diagnostics market, 2015 - 2022 (USD Million)
42. Asia Pacific next generation cancer diagnostics market, 2015 - 2022 (USD Million)
43. China next generation cancer diagnostics market, 2015 - 2022 (USD Million)
44. Japan next generation cancer diagnostics market, 2015 - 2022 (USD Million)
45. Latin America next generation cancer diagnostics market, 2015 - 2022 (USD Million)
46. Brazil next generation cancer diagnostics market, 2015 - 2022 (USD Million)
47. MEA next generation cancer diagnostics market, 2015 - 2022 (USD Million)
48. South Africa next generation cancer diagnostics market, 2015 - 2022 (USD Million)

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3640150/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit 
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Next Generation Cancer Diagnostics Market Size & Forecast By Technology, By Function, By Cancer Type, By Application And Trend Analysis From 2015 To 2022
Web Address: http://www.researchandmarkets.com/reports/3640150/
Office Code: SCH3YODX

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4700</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 8000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: __________________________________________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: _______________________________________________________
Fax Number: _______________________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World